BioCentury | Jan 14, 2017
Strategy

Solidifying Takeda’s position

...last June, Takeda returned Japanese rights to the most advanced cancer compound in its pipeline: trebananib...
BioCentury | Jul 11, 2016
Company News

Amgen, Takeda deal

...said it returned its Japanese rights to fulranumab ( AMG 403 ) and trebananib ( AMG 386...
...under a 2008 deal. In April 2015, Amgen said it terminated Phase III testing of trebananib...
BioCentury | Jun 25, 2016
Company News

Takeda ends Japan deal for two Amgen candidates

...said it returned its Japanese rights to fulranumab ( AMG 403 ) and trebananib ( AMG 386...
...Extra, April 1) . In April 2015, Amgen said it terminated Phase III development of trebananib...
BioCentury | May 30, 2016
Strategy

Taking Takeda global

...The most advanced candidate has the potential to be first in class - trebananib ( AMG 386...
...endpoint of overall survival. Takeda has Japanese rights to the molecule from Amgen Inc. Behind trebananib...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial...
BioCentury | Jan 5, 2015
Finance

4Q14 Stock Wrap-up: Grow early, grow often

...mITT) analysis when four exceptional responders were removed from the placebo group. Amgen Inc. (NASDAQ:AMGN) Trebananib...
...intent-to-treat (mITT) analysis when four exceptional responders were removed from the placebo group.Amgen Inc. (NASDAQ:AMGN) Trebananib...
BioCentury | Nov 10, 2014
Clinical News

Trebananib: Additional Phase III data

...III trials evaluating trebananib in ovarian cancer. Data from the Phase III TRINOVA-2 trial evaluating trebananib...
...tube cancer are expected next year. Takeda has exclusive Japanese rights to trebananib from Amgen. Trebananib...
...Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Trebananib ( AMG 386...
BioCentury | Nov 5, 2014
Clinical News

Amgen's trebananib misses Phase III OS endpoint

...Amgen Inc. (NASDAQ:AMGN) reported that trebananib failed to improve overall survival among recurrent platinum-resistant ovarian cancer...
...top-line secondary endpoint of statistically significant improvement of OS. Amgen reported in June 2013 that trebananib...
...recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins, plus paclitaxel. Two other Phase III trials of trebananib...
BioCentury | Oct 27, 2014
Strategy

Amgen on notice

...in its $1.2 billion acquisition of Micromet Inc. in 2012. In June 2013, Amgen said trebananib...
...imbalance of deaths favoring the control arm." The OS data are expected by year end. Trebananib...
...candidate Procoralan ivabradine with estimated revenues of $396 million; talimogene laherparepvec at $440 million and trebananib...
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...partners restructured their co-development deal, giving Takeda exclusive, worldwide rights to motesanib. Another late-stage candidate, trebananib...
...ANGPT1 ) and angiopoietin 2 ( ANG2 ; ANGPT2 ). In June 2013, Amgen said trebananib...
...arm was observed." OS data are expected by year end. Takeda has exclusive rights to trebananib...
Items per page:
1 - 10 of 44